|
Mean number of presumptive TB cases per day
|
44 (34,55)
|
Data collated from primary health care facilities in Porto Alegre for the PROVE-IT trial [11]
|
|
TB prevalence amongst presumptive-TB cases
|
15.8% (14.6, 17.0%)
|
|
HIV prevalence in TB cases
|
44.8% (40.4, 49.2%)
|
|
HIV prevalence in no TB cases
|
27.3% (25.8, 28.8%)
|
|
Sensitivity - Smear microscopy for HIV-positive
|
45% (38, 52%)
|
Boehme et al [35]
|
|
Specificity - Smear microscopy for HIV-positive
|
100% (99, 100%)
|
|
Sensitivity - Smear microscopy for HIV-negative
|
72% (69, 75%)
|
|
Specificity - Smear microscopy for HIV-negative
|
99% (99, 100%)
|
|
Sensitivity - Xpert for HIV-positive
|
82% (77, 87%)
|
|
Specificity - Xpert for HIV-positive
|
99% (98, 100%)
|
|
Sensitivity - Xpert for HIV-negative
|
92% (90, 94%)
|
|
Specificity - Xpert for HIV-negative
|
99% (98, 99%)
|
|
Sensitivity - Clinical judgement for HIV-positive
|
49%
|
Estimated from reported TB case volumes in Porto Alegre and assumed sensitivity/specificity of Smear microscopy
|
|
Specificity - Clinical judgement for HIV-positive
|
90%
|
|
Sensitivity - Clinical judgement for HIV-negative
|
77%
|
|
Specificity - Clinical judgement for HIV-negative
|
90%
|
|
Sensitivity of X-ray for abnormalities suggestive of active TB
|
87% (79, 95%)
|
WHO [26]
|
|
Specificity of X-ray for abnormalities suggestive of active TB
|
89% (87, 92%)
|
|
Estimated unit cost per test – Microscopy
|
US$7.20
|
Estimates provided by TB research staff working with the TB program in Porto Alegre
|
|
Estimated unit cost per test – Xpert
|
US$ 17.80
|
|
Estimated unit cost per test – X-ray
|
US$ 6.00
|
|
Estimated % of presumptive-TB cases LTFU
|
10.0%
|
|
Estimated cost to treat TB case in Brazil
|
US$840
|
Laurence et al [36]
|
|
Estimated cost to treat MDR-TB in Brazil
|
US$6313
|
